CorriXR Therapeutics Secures $1M Investment from State of Delaware
"We're excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical trial," said Eric Kmiec, Ph.D., founder & CEO of CorriXR. "This investment will be critical as we complete preclinical studies, scale-up manufacturing, and prepare our investigational new drug (IND) submission."
The State of Delaware's investment in CorriXR is the first $1M investment from the Delaware Accelerator & Seed Capital Program (DASCP), one of four programs awarded under the State Small Business Credit Initiative (SSBCI) federal program from the U.S. Treasury Department. The Division of Small Business is administering Delaware's $60.9 million SSBCI award aimed at providing access to capital for start-up and early-stage businesses.
"Our first $1 million investment is proof that Delaware's path to becoming the Mid-Atlantic hub for Innovation is well underway," said Delaware Division of Small Business Director CJ Bell. "Supporting companies like CorriXR to scale isn't just good business – it's the blueprint for turning that vision into reality."
"This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions," said Delaware Governor Matt Meyer. "By working closely with experts at the Gene Editing Institute, CorriXR is making promising CRISPR therapies a reality for patients faster than ever. This is exactly why the SSBCI program exists—because supporting innovation today means better treatments, stronger businesses, and a brighter future for Delaware."
About CorriXR Therapeutics
CorriXR is developing genetic medicines to transform the treatment of solid tumors. CorriXR's patented non-viral gene editing tool disables transcription factor NRF2, which controls 200+ genes responsible for creating a pro-oncogenic tumor microenvironment. Knockout of NRF2 disrupts cancer cell survival mechanisms and sensitizes them to standard of care, and is being developed as a monotherapy, neoadjuvant or in combination with chemotherapy, radiotherapy, or immunotherapy. CorriXR's platform has potential applications in over 30 types of squamous cell carcinomas by improving treatment efficiency at lower doses, increasing patient eligibility, and reducing dropouts due to side effects—ultimately leading to improved patient outcomes.
Learn more at www.corrixr.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250819018203/en/
Contacts
Jennifer Kmiecjkmiec@corrixr.com 302-689-3032
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Walmart is raising prices because of tariffs. Customers are still flocking to Walmart
Walmart is getting hit by tariffs, like every other business in America. But customers are still flocking to Walmart because they believe the retailer offers them the biggest bang for their buck. The retail behemoth once again on Thursday showed how it uses its size to dominate the industry. Its economies of scale help keep prices as low as possible, even as Trump's tariffs raise costs. Walmart also relies on its strength in groceries and necessities to win over shoppers looking for discounts. More than half of Walmart's sales come from groceries. Walmart said Thursday that sales at US stores open for at least a year jumped 4.8%, and it gained market share across income groups, led by growth with upper-income households. The company also raised its sales outlook for the year. CEO Doug McMillon said that tariffs have created pressures for the company and its seeing its 'costs increase each week.' But it's keeping prices down 'for as long as we can.' Customers have not made major shifts to their purchasing behavior because of tariffs, he said, but some middle and lower-income households have stopped buying some discretionary products that have gone up in prices. 'Value is still en vogue. That's the key message from Walmart,' Neil Saunders, an analyst at GlobalData Retail, said in a note to clients. 'Broad consumer and macro trends remain favorable to Walmart.' Still, Walmart's stock fell 3% during pre-market trading. The company missed analysts' profit forecasts. Heading into Thursday, Walmart's stock had increased 36%. Walmart is surging ahead of its rivals, such as Target and Home Depot. Target, in particular, is in a funk and its CEO is stepping down. Target on Wednesday reported sales fell for the third consecutive quarter. Shares tumbled 6%. Target has been one of the worst-performing stocks on the S&P 500. Target CEO Brian Cornell is stepping down after 11 years at the retailer, as the company faces slumping sales and backlash to its retreat on DEI. He will be replaced early next year by Michael Fiddelke, Target's current chief operating officer. Some investors and analysts criticized the move, arguing Target should have hired an outside voice to lead the company. The company's business is falling behind Walmart because it stocks more non-essential goods such as home decor than Walmart. Many shoppers, strained by inflation over the past several years, are buying fewer discretionary products and focusing on essentials. Target also imports about half of its merchandise, compared to roughly 33% at Walmart, so it needs to raise prices at almost double the rate of Walmart to mitigate the tariff impact, Bank of America analyst Robert Ohmes said in a report this week. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
32,000 pounds of meat products recalled due to false USDA inspection marks
A New Jersey-based company, Sabrositos Hondurenos, LLC, is recalling about 32,000 pounds of various meat products with a false USDA mark of inspection, meaning the meats didn't go through proper federal examination, according to federal officials. In an alert shared Thursday, the U.S. Department of Agriculture's Food Safety and Inspection Service said the recalled products are falsely labeled with establishment number "EST. 1785," which "does not exist," they said. The items, which include chorizo (sausage), pork chops and ribs, were shipped to retail locations and restaurants nationwide and were produced with various dates before Aug. 20, 2025. The recall includes the following: Homestyle chorizo labeled "OLANCHO Chorizo Suelto Olanchano SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked pork chops labeled "OLANCHO Chuleta Ahumada Olanchana SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked chorizo labeled "OLANCHO Chorizo Ahumado Olanchano SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Cased homestyle chorizo labeled "OLANCHO Chorizo Olanchano Criollo SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked BBQ spicy chorizo labeled "OLANCHO Chorizo Parrillero SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked ribs labeled "OLANCHO Costilla Ahumada Olanchana SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages) As more information becomes available, FSIS said it may add more items to the recalled product list, so consumers should keep an eye on the website for updates. So far, there have been no confirmed reports of adverse reactions due to these products, but the USDA says they should be considered "misbranded and unsafe to eat." Anyone concerned about a reaction should contact a healthcare provider, the agency added. Consumers can contact Diego Funez Garrido, owner of Sabrositos Hondurenos, LLC at 908-274-4206 for any questions regarding the recall, the alert added. Trump sounds off on potential security guarantees for Ukraine Man advocates for school zone and driver safety after personal tragedy What to know about the Menendez brothers' parole hearings Solve the daily Crossword
Yahoo
4 minutes ago
- Yahoo
Artisan Value Fund is Confident in its Investment in Thermo Fisher Scientific (TMO). Here's Why
Artisan Partners, an investment management company, released its 'Artisan Value Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets faced significant volatility in the second quarter, fueled by the announcement and subsequent pause of the "Liberation Day" tariffs. Against this backdrop, the fund's Investor Class ARTLX, Advisor Class APDLX, and Institutional Class APHLX returned 5.99%, 5.96%, and 5.96%, respectively, in the second quarter compared to a 3.79% return for the Russell 1000® Value Index. In addition, you can check the top 5 holdings of the strategy to know its best picks in 2025. In its second-quarter 2025 investor letter, Artisan Value Fund highlighted stocks such as Thermo Fisher Scientific Inc. (NYSE:TMO). Thermo Fisher Scientific Inc. (NYSE:TMO) offers life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services. The one-month return of Thermo Fisher Scientific Inc. (NYSE:TMO) was 4.16%, and its shares lost 18.91% of their value over the last 52 weeks. On August 20, 2025, Thermo Fisher Scientific Inc. (NYSE:TMO) stock closed at $494.81 per share, with a market capitalization of $186.846 billion. Artisan Value Fund stated the following regarding Thermo Fisher Scientific Inc. (NYSE:TMO) in its second quarter 2025 investor letter: "Thermo Fisher Scientific Inc. (NYSE:TMO) is a life science tools and clinical research company serving a range of end markets, including pharmaceutical, clinical, academia, industrial and applied sciences. The company has a leading industry position in a market that grows about 4%–6%peryear, though we believe core organic growth can be1%–2%overthatduetoTMO'sdominantpositionsinavariety of fast-growing end markets, like rare disease and genomics. The company has a solid balance sheet, high free cash flow conversion a history of good capital allocation comprised of R&D, M&A and return of capital (buybacks and dividends). End markets were already cyclically depressed, but tariffs and government spending cuts may delay a recovery. These concerns allowed us an attractive entry point of 17X2026expected earnings. The vast majority of TMO's revenue is recurring, primarily from consumables, which gives us increased confidence in our investment case while the company manages tariff impacts and as we wait for end markets to mend." A workstation in a research lab stocked with laboratory products and services. Thermo Fisher Scientific Inc. (NYSE:TMO) is in 26th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 101 hedge fund portfolios held Thermo Fisher Scientific Inc. (NYSE:TMO) at the end of the first quarter, which was 100 in the previous quarter. Thermo Fisher Scientific Inc.'s (NYSE:TMO) revenue in the second quarter grew 3% to $10.85 billion. While we acknowledge the potential of Thermo Fisher Scientific Inc. (NYSE:TMO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Thermo Fisher Scientific Inc. (NYSE:TMO) and shared Parnassus Investments' views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
